斯菱股份(301550.SZ):斯菱泰國第二期投資的全產業鏈工序已基本完成,逐步進入量產階段
格隆匯5月15日丨斯菱股份(301550.SZ)於近日接受特定對象調研,就“斯菱未來業績增長的驅動因素有哪些?”,公司回覆稱,主業方面,公司將持續開拓全球售後市場,每年保持穩定增速,同時公司積極推進主機市場的業務開拓;海外佈局方面,斯菱泰國第二期投資的全產業鏈工序已基本完成,逐步進入量產階段,公司已啟動第三期投資,持續完善全產業鏈配套工序,計劃2024年Q2完成。國內募投項目和泰國投資完成達產,將提高公司現有產能,為後續的開拓發展打好基礎。機器人零部件方面,公司密切關注市場動態,提前做好產品研發及量產準備,將根據市場需求情況制定合適的量產規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.